|Headquarters||Brentford, Greater London, UK|
|Deborah Waterhouse, (CEO), replaced Dominique Limet in April 2017|
ViiV Healthcare (// VEEV) is a pharmaceutical company specialising in the development of therapies for HIV infection that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi. This ownership structure may change depending upon the achievement of certain milestones.
ViiV Healthcare's products have a market share of approximately 19% of the global HIV market, which makes it the second largest healthcare company, following after Gilead Sciences, that is working on the treatment of HIV.
ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.
- Nucleoside reverse transcriptase inhibitors (NRTIs):
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- delavirdine (brand name Rescriptor)
- Integrase strand transfer inhibitors (INSTIs):
- dolutegravir (brand name Tivicay)
- Protease inhibitors:
- Entry inhibitors:
- maraviroc (brand names Selzentry and Celsentri)
- Antiretroviral fixed-dose combinations, including several single-pill regimens:
- abacavir/lamivudine (brand names Epzicom and Kivexa)
- abacavir/lamivudine/zidovudine (brand name Trizivir)
- lamivudine/zidovudine (brand name Combivir)
- abacavir/dolutegravir/lamivudine (brand name Triumeq)
- dolutegravir/lamivudine (brand name Dovato)
- dolutegravir/rilpivirine (brand name Juluca - in partnership with Janssen Pharmaceutica)
Treatment access programs
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low and middle income countries, as well as all of Sub-Saharan Africa.
The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.
- Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
- "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
- "ViiV Healthcare Company Website. About Us — At a Glance" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
- Jacks, Andrew "ViiV Vows Joint Venture Will Help Fight HIV" Financial Times. 3 November 2009 (subscription required)
- "ViiV Healthcare Company Website. About Us — Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
- ViiV Healthcare Company Website. Our Medicines. Archived 28 February 2017 at the Wayback Machine Accessed 21 July 2017
- McNeil, Donald "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease" New York Times. 9 November 2009
- "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
- Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa — the Good News. 19 July 2010